Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double Blind, Placebo Controlled Study of Deutenzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With High-Risk Biochemical Recurrence (BCR) of Prostate Cancer

NCT07875881 is registered in ClinicalTrials.gov with Hinova Pharmaceuticals Inc. as lead sponsor.

NCT NCT07875881
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07875881 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double Blind, Placebo Controlled Study of Deutenzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With High-Risk Biochemical Recurrence (BCR) of Prostate Cancer
Lead sponsor
Hinova Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
December 31, 2031
Enrollment
1,044 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

deutenzalutamide soft capsules, high risk biochemical recurrence (bcr)